Physician profile
Amara D Wright-Terry
NPI 1043722622
$17,151.49
in general payments reported to CMS, 2019-2025
28 companies · $1,622 in 2025
The $1,622 reported for 2025 was more than what 93% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,910 · 2022: $4,306 · 2023: $5,831 · 2024: $3,482 · 2025: $1,622.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,945 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $875 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,944.73 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $875.00 |
| Education | $116.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,690.49 | 2021-2025 | |
| Janssen Biotech, INC. | $1,767.25 | 2021-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $1,496.54 | 2021-2025 | Entyvio, Eohilia |
| Nestle Healthcare Nutrition INC. | $1,493.45 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,115.50 | 2021-2025 | Trulance, Xifaxan, Relistor |
| Celgene Corporation | $558.41 | 2022-2024 | Zeposia |
| Ardelyx, INC. | $466.59 | 2022-2025 | Ibsrela |
| Qol Medical, LLC | $376.44 | 2023-2025 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $357.06 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $271.32 | 2021-2023 | Dificid, Zinplava |
| Madrigal Pharmaceuticals | $266.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $261.65 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $232.49 | 2021-2023 | Stelara |
| Genzyme Corporation | $223.92 | 2023-2025 | |
| Evoke Pharma, INC. | $199.39 | 2021-2023 | Gimoti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $181.97 | 2022-2023 | Zeposia |
| Lilly USA, LLC | $171.91 | 2024-2025 | Omvoh |
| Olympus America INC. | $148.05 | 2024 | Endocapsule Recorder, Visiglide, Hanarostent Esophagus Tts(Ccc) |
| Braintree Laboratories, INC. | $124.25 | 2021-2023 | Sutab, Suflave |
| Vivus LLC | $123.17 | 2021-2023 | Pancreaze |
| Aimmune Therapeutics, INC. | $119.38 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $95.70 | 2021-2023 | Linzess |
| Sandoz INC. | $87.90 | 2023-2024 | Hyrimoz |
| Ferring Pharmaceuticals INC. | $85.41 | 2022-2025 | Rebyota |
| Redhill Biopharma INC. | $78.95 | 2021 | |
| Gilead Sciences, INC. | $75.74 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.63 | 2023-2024 | Cyltezo |
| Regeneron Healthcare Solutions, INC. | $39.59 | 2024 | Dupixent |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amara Wright-Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.